



<b>NAME</b>	<b>MR. RAMKUMAR</b>	<b>PATIENT ID</b>	<b>I-185638</b>
<b>ACCESSION NO</b>	<b>172872</b>	<b>AGE/GENDER</b>	<b>39Y/MALE</b>
<b>REFERRED BY</b>	<b>MEDIWHEEL</b>	<b>DATE</b>	<b>27-JULY-2024</b>

**ECHOCARDIOGRAPHIC EVALUATION**

**MEASUREMENTS: ACOUSTIC WINDOW: OPTIMAL**

**2D/ M MODE PARAMETERS:**

<b>Parameters</b>	<b>Patient Values</b>	<b>Normal Adult Value</b>
LA	3.79	(2.0-4.0 cm)
AO	3.25	(2.0-4.0 cm)
LVIDD	4.62	(3.5-5.5 cm)
LVIDS	2.75	(2.5-4.3 cm)
IVSd	1.03	(0.6-1.2 cm)
LVPWd	1.08	(0.6-1.2 cm)
EF	71	(50% - 70%)

**IMPRESSION:**

- ✚ No regional wall motion abnormality at rest.
- ✚ Normal valves and chambers.
- ✚ Grade II diastolic dysfunction.( E/A=1.39, E/e = 10.48)
- ✚ No pulmonary hypertension.
- ✚ No pericardial effusion.
- ✚ Normal LV systolic function.



Dr. KARTHIK C.S.MD., PGD(CARDIOLOGY,UKR)  
CONSULTANT CARDIOLOGIST  
TMC(REF) No. 88567

**Dr. KARTHIK C.S.MD.,PGD(CARDIOLOGY,UKR)**

**CONSULTANT CARDIOLOGIST.**

# ABI SCANS & LABS

MR. RAMKUMAR S 39Y/M I- 185638 27-Jul-2024 04:16:49 PM






# Aarthi CT and MRI Scans, R S Puram West

Age / Gender: 39/Male  
Date and Time: 27th Jul 24 12:10 PM

Patient ID: 0000185638

Patient Name: MR. RAMKUMAR S

BP-140/90mmHg



Copyright 2014-2024 Tricog Health. All Rights Reserved.

AR: 77bpm    VR: 77bpm    QT: 358ms    QTcB: 405ms    PRI: 164ms    P-R-T: 43° 30° -2°

in Normal Limits: Sinus Rhythm. Please correlate clinically.



this report is based on ECG alone and should only be used as an adjunct to clinical history, symptoms and results of other invasive and non-invasive tests and must be interpreted by a qualified physician.


**ABI SCANS & LABS**<sup>TM</sup>

Accurate | Available | Affordable

**Patient Name :** MR. RAMKUMAR S

**Age / Gender :** 39 years / Male

**Patient ID :** 172872

**Referral :** MediWheel

Scan to Validate


**Billing Time :** Jul 27, 2024, 10:23 a.m.

**Collection Time :** Jul 27, 2024, 10:35 a.m.

**Reporting Time :** Jul 27, 2024, 01:42 p.m.

**Sample ID :**


002520924

Test Description	Value(s)	Unit(s)	Reference Range
<b><u>COMPLETE BLOOD COUNT ( CBC )</u></b>			
Hemoglobin (Hb)	15.4	gm/dL	13.5 - 18.0
Erythrocyte (RBC) Count	4.99	mil/cu.mm	4.7 - 6.0
Packed Cell Volume (PCV)	43.2	%	42 - 52
Mean Cell Volume (MCV)	86.57	fL	78 - 100
Mean Cell Haemoglobin (MCH)	30.86	pg	27 - 31
Mean Corpuscular Hb Concn. (MCHC)	35.65	g/dL	32 - 36
Red Cell Distribution Width (RDW)	13.0	%	11.5 - 14.0
Total Leucocytes (WBC) Count	5140	cell/cu.mm	4000-10000
Neutrophils	48	%	40 - 80
Lymphocytes	40	%	20 - 40
Monocytes	10	%	2 - 10
Eosinophils	2	%	1 - 6
Basophils	0	%	1-2
Absolute Neutrophil Count	2467.20	/c.mm	2000 - 7000
Absolute Lymphocyte Count	2056	/c.mm	1000 - 3000
Absolute Monocyte Count	514	/c.mm	200 - 1000
Absolute Eosinophil Count	102.80	/c.mm	20 - 500
Absolute Basophils Count	0	/c.mm	20 - 100
Platelet Count	248	10 <sup>3</sup> /ul	150 - 450
Mean Platelet Volume (MPV)	8.7	fL	7.2 - 11.7
PCT	0.22	%	0.2 - 0.5
PDW	9.0	%	9.0 - 17.0
ESR	10	mm/hr	13.5 - 18.0

**GLUCOSE (F)**



 DR.K.MURALEKARTHIC  
MD(Patho)


**ABI SCANS & LABS**<sup>TM</sup>

Accurate | Available | Affordable

**Patient Name :** MR. RAMKUMAR S

**Age / Gender :** 39 years / Male

**Patient ID :** 172872

**Referral :** MediWheel

Scan to Validate


**Billing Time :** Jul 27, 2024, 10:23 a.m.

**Collection Time :** Jul 27, 2024, 10:35 a.m.

**Reporting Time :** Jul 27, 2024, 01:42 p.m.

**Sample ID :**


002520924

Test Description	Value(s)	Unit(s)	Reference Range
------------------	----------	---------	-----------------

Glucose fasting Method : GOD-POD	96.0	mg/dL	70 - 120
-------------------------------------	------	-------	----------

**GLUCOSE (PP)**

Blood Glucose-Post Prandial Method : GOD-POD	110.0	mg/dL	80 - 140
---	-------	-------	----------

**Glycosylated HbA1c**

<b>HbA1c (GLYCOSYLATED HEMOGLOBIN)</b> Method : (HPLC, NGSP certified)	5.1	%	
---	-----	---	--

Estimated Average Glucose :	99.67	mg/dL	-
-----------------------------	-------	-------	---

**Interpretation**

As per American Diabetes Association (ADA)	
Reference Group	HbA1c in %
Non diabetic adults >=18 years	<5.7
At risk (Prediabetes)	5.7 - 6.4
Diagnosing Diabetes	>= 6.5
Therapeutic goals for glycemic control	Age > 19 years Goal of therapy: < 7.0 Action suggested: > 8.0 Age < 19 years Goal of therapy: <7.5

**BLOOD GROUP & RH TYPING**

Blood Group (ABO typing) Method : Manual-Hemagglutination	"O"
RhD Factor (Rh Typing) Method : Manual hemagglutination	Negative

 DR.K.MURALEKAARTHIC  
MD(Patho)


**ABI SCANS & LABS**<sup>TM</sup>

Accurate | Available | Affordable

**Patient Name :** MR. RAMKUMAR S

**Age / Gender :** 39 years / Male

**Patient ID :** 172872

**Referral :** MediWheel

Scan to Validate


**Billing Time :** Jul 27, 2024, 10:23 a.m.

**Collection Time :** Jul 27, 2024, 10:35 a.m.

**Reporting Time :** Jul 27, 2024, 01:42 p.m.

**Sample ID :**


002520924

Test Description	Value(s)	Unit(s)	Reference Range
------------------	----------	---------	-----------------

**RENAL PROFILE**

Urea Method : Uricase	23.0	mg/dL	19-42
Blood Urea Nitrogen-BUN Method : Serum, Urease	10.73	mg/dL	9-20
Creatinine Method : Serum, Jaffe	0.67	mg/dL	0.66-1.25
Uric Acid Method : Serum, Uricase	3.7	mg/dL	3.5-8.5

**Remark:**

In blood, Urea is usually reported as BUN and expressed in mg/dl. BUN mass units can be converted to urea mass units by multiplying by 2.14.

**LIVER FUNCTION TEST**

Total Protein Method : Serum, Biuret, reagent blank end point	7.3	g/dL	6.3-8.2
Albumin Method : Serum, Bromocresol green	3.8	g/dL	3.5-5.0
Globulin Method : Serum, EIA	3.50	g/dL	1.8 - 3.6
A/G Ratio Method : Serum, EIA	<b>1.09</b>		1.2 - 2.2
Bilirubin - Total Method : Serum, Jendrassik Grof	0.6	mg/dL	0.3-1.2
Bilirubin - Direct Method : Serum, Diazotization	0.1	mg/dL	< 0.2
Bilirubin - Indirect Method : Serum, Calculated	0.50	mg/dL	0.1 - 1.0

 DR.K.MURALEKAARTHIC  
MD(Patho)



**ABI SCANS & LABS**<sup>TM</sup>

Accurate | Available | Affordable

**Patient Name** : MR. RAMKUMAR S

**Age / Gender** : 39 years / Male

**Patient ID** : 172872

**Referral** : MediWheel

Scan to Validate



**Billing Time** : Jul 27, 2024, 10:23 a.m.

**Collection Time** : Jul 27, 2024, 10:35 a.m.

**Reporting Time** : Jul 27, 2024, 01:42 p.m.

**Sample ID** :




002520924

Test Description	Value(s)	Unit(s)	Reference Range
SGOT Method : Serum, UV with P5P, IFCC 37 degree	25.0	U/L	17-59
SGPT Method : Serum, UV with P5P, IFCC 37 degree	34.0	U/L	21-72
Alkaline Phosphatase Method : PNPP-AMP Buffer/Kinetic	67.0	U/L	30 - 120
GGT-Gamma Glutamyl Transpeptidase Method : Serum, G-glutamyl-carboxy-nitroanilide	13.0	U/L	< 55

#### LIPID PROFILE

Cholesterol-Total Method : Spectrophotometry	176.0	mg/dL	Desirable level   < 200 Borderline High   200-239 High   >or = 240
Triglycerides Method : Serum, Enzymatic, endpoint	87.0	mg/dL	Normal: < 150 Borderline High: 150-199 High: 200-499 Very High: >= 500
HDL Cholesterol Method : Serum, Direct measure-PEG	47.0	mg/dL	Normal: > 40 Major Risk for Heart: < 40
LDL Cholesterol Method : Enzymatic selective protection	111.60	mg/dL	Optimal < 100 Near / Above Optimal 100-129 Borderline High 130-159 High 160-189 Very High >or = 190
VLDL Cholesterol Method : Serum, Enzymatic	17.40	mg/dL	6 - 38
CHOL/HDL Ratio Method : Serum, Enzymatic	3.74		3.5 - 5.0

  
DR.K.MURALEKAARTHIC  
MD(Patho)


**ABI SCANS & LABS**<sup>TM</sup>

Accurate | Available | Affordable

**Patient Name :** MR. RAMKUMAR S

**Age / Gender :** 39 years / Male

**Patient ID :** 172872

**Referral :** MediWheel

Scan to Validate


**Billing Time :** Jul 27, 2024, 10:23 a.m.

**Collection Time :** Jul 27, 2024, 10:35 a.m.

**Reporting Time :** Jul 27, 2024, 01:42 p.m.

**Sample ID :**


002520924

Test Description	Value(s)	Unit(s)	Reference Range
LDL/HDL Ratio Method : Serum, Enzymatic	2.37		2.5 - 3.5

**Note:**

8-10 hours fasting sample is required.

**THYROID PROFILE TEST - TOTAL**

T3-Total	105.4	ng/dL	60 - 200
T4-Total	8.51	ug/dL	4.52 - 12.8
TSH-Ultrasensitive Method : CLIA	1.55	uIU/mL	0.32 - 5.5

**PSA-Total (Prostate-specific antigen-Total)**
**PSA Profile \***

PSA (Prostate Specific Antigen)-Total Method : Serum, CLIA	0.74	ng/mL	0 - 4.0
---	------	-------	---------

**Interpretation:**

1. Increased levels are noted in Prostate cancer, Benign prostatic hypertrophy, Prostatitis

PSA (Prostate-Specific antigen)-Free * Method : Serum, CLIA	-	ng/mL	0.0 - 0.5
--	---	-------	-----------

**Interpretation & Remarks:**

- Normal results do not eliminate the possibility of prostate cancer.
- Values obtained with different assay methods or kits may be different and cannot be used interchangeably.
- Tumor markers are not specific for malignancy. Test results cannot be interpreted as absolute evidence for the presence or absence of malignant disease
- Specimens drawn from patients undergoing prostate manipulation, especially needle biopsy and transurethral resection, may show erroneously high prostatic-specific antigen (PSA) results. Care should be taken that specimens are drawn before these procedures are performed.
- The percentage of free PSA can be used to estimate how likely it is that a biopsy will show cancer.

 DR.K.MURALEKAARTHIC  
MD(Patho)




**ABI SCANS & LABS**<sup>TM</sup>

Accurate | Available | Affordable

**Patient Name :** MR. RAMKUMAR S

**Age / Gender :** 39 years / Male

**Patient ID :** 172872

**Referral :** MediWheel

Scan to Validate


**Billing Time :** Jul 27, 2024, 10:23 a.m.

**Collection Time :** Jul 27, 2024, 10:35 a.m.

**Reporting Time :** Jul 27, 2024, 01:42 p.m.

**Sample ID :**


002520924

Test Description	Value(s)	Unit(s)	Reference Range
------------------	----------	---------	-----------------

- If the percentage of free PSA is higher than 25%, the likelihood of prostate cancer is about 8%.
- If the percentage of free PSA is less than 10%, then the likelihood of prostate cancer rises to 56%.

Free PSA / Total PSA %

-

-

Method : Serum

**Interpretation**

- When total prostate-specific antigen (PSA) concentration is <2.0 ng/mL, the probability of prostate cancer in asymptomatic men is low, further testing and free PSA may provide little additional information. When total PSA concentration is >10.0 ng/mL, the probability of cancer is high and prostate biopsy is generally recommended.
- The total PSA range of 4.0 to 10.0 ng/mL has been described as a diagnostic "gray zone," in which the free:total PSA ratio helps to determine the relative risk of prostate cancer (see table below). Therefore, some urologists recommend using the free:total ratio to help select which men should undergo biopsy. However even a negative result of prostate biopsy does not rule-out prostate cancer. Up to 20% of men with negative biopsy results have subsequently been found to have cancer.

Based on free:total PSA ratio: the percent probability of finding prostate cancer on a needle biopsy by age in years:

Free:total PSA ratio	50-59 years	60-69 years	> or =70 years
< or =0.10	49.2%	57.5%	64.5%
0.11-0.18	26.9%	33.9%	40.8%
0.19-0.25	18.3%	23.9%	29.7%
>0.25	9.1%	12.2%	15.8%

**Cautions**

- Normal results do not eliminate the possibility of prostate cancer.
- Values obtained with different assay methods or kits may be different and cannot be used interchangeably
- Tumor markers are not specific for malignancy. Test results cannot be interpreted as absolute evidence for the presence or absence of malignant disease.

**Interfering factors :**



 DR.K.MURALEKARTHIC  
MD(Patho)


**ABI SCANS & LABS**<sup>TM</sup>

Accurate | Available | Affordable

**Patient Name :** MR. RAMKUMAR S

**Age / Gender :** 39 years / Male

**Patient ID :** 172872

**Referral :** MediWheel

Scan to Validate


**Billing Time :** Jul 27, 2024, 10:23 a.m.

**Collection Time :** Jul 27, 2024, 10:35 a.m.

**Reporting Time :** Jul 27, 2024, 01:42 p.m.

**Sample ID :**


002520924

Test Description	Value(s)	Unit(s)	Reference Range
<ul style="list-style-type: none"> <li>Prostatic massage</li> <li>Proctoscopy</li> <li>Prostatic biopsy</li> <li>Prostate cancer patients receiving treatment with antiandrogens and luteinizing hormone-releasing factor agonists may exhibit markedly decreased levels of PSA. Also, men treated for benign prostatic hyperplasia with inhibitors of 5-alpha-reductase (finasteride) may demonstrate a significant reduction in PSA levels compared to values before treatment. Care should be taken in interpreting values for these individuals.</li> <li>In patients receiving therapy with high biotin doses (ie, &gt;5 mg/day), no sample should be taken until at least 8 hours after the last biotin administration.</li> </ul>			

**URINE GLUCOSE (PP)**

URINE GLUCOSE (PP) Nil

**URINE COMPLETE ANALYSIS,**
**Physical Examination**

Quantity	30	ml	-
Colour	Pale Yellow		Pale yellow/Yellow
Appearance	Clear		Clear
Specific Gravity	1.010		1.005-1.025
pH	5.0		5.0 - 8.0
Deposit	Present		Absent

**Chemical Examination**

Protein	Absent		Absent
Sugar	Absent		Absent
Ketones	Absent		Absent
Bile Salt	Absent		Absent

 DR.K.MURALEKAARTHIC  
MD(Patho)



**ABI SCANS & LABS**<sup>TM</sup>

Accurate | Available | Affordable

**Patient Name :** MR. RAMKUMAR S

**Age / Gender :** 39 years / Male

**Patient ID :** 172872

**Referral :** MediWheel

Scan to Validate



**Billing Time :** Jul 27, 2024, 10:23 a.m.

**Collection Time :** Jul 27, 2024, 10:35 a.m.

**Reporting Time :** Jul 27, 2024, 01:42 p.m.

**Sample ID :**



002520924

Test Description	Value(s)	Unit(s)	Reference Range
<b>Bile Pigment</b>	Absent		Absent
<b>Urobilinogen</b>	Normal		Normal
<b><u>Microscopic Examination (/hpf)</u></b>			
<b>Pus Cell</b>	2-4		Upto 5
<b>Epithelial Cells</b>	2-4		Upto 5
<b>Red Blood Cells</b>	Absent		Absent
<b>Casts</b>	Absent		Absent
<b>Crystals</b>	Absent		Absent
<b>Amorphous Deposit</b>	Absent		Absent
<b>Yeast Cells</b>	Absent		Absent
<b>Bacteria</b>	Absent		Absent
<b>Other findings</b>	Not seen		Not seen

DR.K.MURALEKAARTHIC  
MD(Patho)



**ABI SCANS & LABS**<sup>TM</sup>

Accurate | Available | Affordable

Patient Name	MR RAMKUMAR S	Age	39Yr
Patient ID	172872	Sex	Male
Referral Dr	MEDIWHEEL	Study Date	27 Jul 2024

**X-RAY - CHEST PA VIEW**

**OBSERVATION:**

The trachea is central.

The mediastinal and cardiac silhouette are normal.

Cardiothoracic ratio is normal.

Cardiophrenic and costophrenic angles are normal.

Both hila are normal.

Lung zones are clear.

Bones of the thoracic cage are normal.

Soft tissues of the chest wall are normal.

**IMPRESSION:**

- No significant abnormality seen.

Dr. Lokesh Babu., MD., (RD)  
Consultant Radiologist



Patient Name	MR.S.RAMKUMAR	Age	39Yr
Patient ID	172872	Sex	Male
Referral Dr	MEDIWHEEL	Study Date	27 Jul 2024

### USG REPORT - ABDOMEN AND PELVIS

#### LIVER:

Is normal in size ~ 12.4 cm and shows increased echo texture.

No obvious focal lesion seen. No intra – Hepatic biliary radical dilatation seen.

#### GALL BLADDER:

Is adequately distended. No calculus or internal echoes are seen. Wall thickness is normal.

#### PANCREAS:

Appears normal in size and it shows uniform echo texture.

#### SPLEEN:

Is normal in size ~ 11.8 cm and shows uniform echogenicity.

#### RIGHT KIDNEY:

Right kidney measures ~ 9.1 x 4.7 cms.

The shape, size and contour of the right kidney appear normal.

Cortico medullary differentiation is within normal. No evidence of pelvicalyceal dilatation.

No calculi seen.

#### LEFT KIDNEY:

Left kidney measures ~ 11.7 x 5 cms.

The shape, size and contour of the left kidney appear normal.

Cortico medullary differentiation is within normal. No evidence of pelvicalyceal dilatation.

No calculi seen.

#### BLADDER:

Is normal contour. No intra luminal echoes are seen.

#### PROSTATE:

Appears normal in size, measures ~ 3.2 x 3.1 x 3 cm (Vol - 16.2 cc)



**ABI SCANS & LABS**™

Accurate | Available | Affordable

Patient Name	MR.S.RAMKUMAR	Age	39Yr
Patient ID	172872	Sex	Male
Referral Dr	MEDIWHEEL	Study Date	27 Jul 2024

**RIGHT ILIAC FOSSA:**

No focal fluid collections seen.

No evidence of hernia seen in anterior abdominal wall.


**IMPRESSION:**


- Grade I fatty liver.
- No other significant abnormality seen in the present study.
- Suggested clinical correlation.

*Abinaya R*

Dr. Abinaya., MD., (RD)  
Consultant Radiologist.

*Dr. Abinaya Rajasekaran, MD., RD.,*  
Reg. No: 119338





<b>NAME</b>	<b>MR. RAMKUMAR S</b>	<b>PATIENT ID</b>	<b>I-185638</b>
<b>ACCESSION NO</b>	<b>172872</b>	<b>AGE/GENDER</b>	<b>39Y/MALE</b>
<b>REFERRED BY</b>	<b>MEDIWHEEL</b>	<b>DATE</b>	<b>27-JULY-2024</b>

## VISION TEST

### VISUAL ACUITY (VA)

If The Acuity Can Be Measures, Complete This Box Using Snellen acuities or snellen equivalentents or NLP,LP,HM, or distance at which the patient sees the 20/100 letter.

### WITH BEST CORRECTION

<b>DISTANCE VISION</b>	
<b>Right</b>	<b>08/11</b>
<b>Left</b>	<b>08/11</b>
<b>Both</b>	<b>10/11</b>

<b>NEAR VISION</b>	
<b>Right</b>	<b>N6</b>
<b>Left</b>	<b>N6</b>
<b>Both</b>	<b>N6</b>

<b>COLOUR VISION</b>	
<b>BOTH</b>	<b>Normal</b>